LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Amicus Therapeutics Inc

Chiusa

SettoreSettore sanitario

5.99 -0.99

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.97

Massimo

6.23

Metriche Chiave

By Trading Economics

Entrata

-36M

-22M

Vendite

-24M

125M

EPS

0.03

Margine di Profitto

-17.314

Dipendenti

499

EBITDA

-27M

-4.8M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+163.16% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-217M

2.1B

Apertura precedente

6.98

Chiusura precedente

5.99

Notizie sul Sentiment di mercato

By Acuity

50%

50%

195 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 mag 2025, 23:59 UTC

Notizie principali
Utili

Naver 1Q Net Slumps on Higher Costs

8 mag 2025, 23:39 UTC

Utili

OCBC 1Q Net Down on Lower Interest Income

8 mag 2025, 23:01 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mag 2025, 22:52 UTC

Utili

REA Expects Annual Listings Growth Despite April Decline

8 mag 2025, 22:46 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mag 2025, 23:41 UTC

Discorsi di Mercato

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mag 2025, 23:30 UTC

Utili

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mag 2025, 23:29 UTC

Utili

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mag 2025, 23:05 UTC

Discorsi di Mercato

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mag 2025, 23:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:01 UTC

Notizie principali

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mag 2025, 22:28 UTC

Utili

REA Expects FY 2025 Listings Growth of 1-2%

8 mag 2025, 22:28 UTC

Utili

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mag 2025, 22:27 UTC

Utili

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mag 2025, 22:27 UTC

Utili

REA Says April Residential Listings Fell by 11% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

163.16% in crescita

Previsioni per 12 mesi

Media 16 USD  163.16%

Alto 22 USD

Basso 12 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

7

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.925 / 7.38Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

195 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.